Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pertuzumab-dpzb + trastuzumab-strf
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Poherdy + Hercessi is a combination of two HER2-targeted monoclonal antibody biosimilars: Poherdy (pertuzumab-dpzb) and Hercessi (trastuzumab-strf). Poherdy is an interchangeable biosimilar to Perjeta (pertuzumab), developed by Shanghai Henlius Biotech and commercialized in partnership with Organon. Hercessi is a biosimilar to Herceptin (trastuzumab), developed by Shanghai Henlius Biotech and commercialized in partnership with Accord BioPharma. Both monoclonal antibodies target the human epidermal growth factor receptor 2 (HER2) but bind to different extracellular domains (subdomain II for pertuzumab and subdomain IV for trastuzumab), providing synergistic inhibition of HER2-mediated signaling and tumor cell proliferation. The combination is indicated, alongside chemotherapy, for the treatment of patients with HER2-positive breast cancer, including metastatic breast cancer, and as neoadjuvant or adjuvant therapy for early-stage or locally advanced breast cancer. Both agents are administered via intravenous infusion.
- Brand names
- HANBEIYOU + HANQUYOUHANBEIYOU + HERCESSIPOHERDY + HANQUYOUPoherdy + HercessiZercepac + HANBEIYOUZercepac + Poherdy
- Other names
- pertuzumab + trastuzumabpertuzumab-dpzb + trastuzumab-strf
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on pertuzumab-dpzb + trastuzumab-strf.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pertuzumab-dpzb + trastuzumab-strf.